At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers
In Brief
A Phase 2 clinical trial evaluating Placebo and Thymosin Beta 4 for Pressure Ulcers. Completed, enrolled 72 participants across 12 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPressure Ulcers
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedSep 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedSep 28, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.8 years ago
Interventions
Placebodrug
Topical administration of 0.00% thymosin beta 4 qd up to 84 days
Thymosin Beta 4drug
Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days